Online inquiry

IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (CAT#: GTTS-WQ11142MR)

This product GTTS-WQ11142MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IFNA1 gene. The antibody can be applied in Dermatomyositis research.

Specifications
Product type	mRNA
Modified bases	2-Thio-UTP
5' Cap	Cap 1
Species	Homo sapiens
RefSeq	NM_024013.3
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	3439
UniProt ID	P01562

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ11142MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ11268MR	IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	MEDI4893
GTTS-WQ8010MR	IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	GZ-402668
GTTS-WQ8664MR	IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	HuMax-CD38
GTTS-WQ11635MR	IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	MGD-013
GTTS-WQ13301MR	IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 0, 2-Thio-UTP, 30 nt-poly(A))	mRNA	PF-06523435
GTTS-WQ10873MR	IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 0, 2-Thio-UTP, 30 nt-poly(A))	mRNA	MAb-14.18
GTTS-WQ9935MR	IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 0, 2-Thio-UTP, 120 nt-poly(A))	mRNA	KB-004
GTTS-WQ7221MR	IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	FMC63 scFv-G4h-28-F9Z-TpERt CAR

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST